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Topiramate is a recently licensed and marketed antiepileptic drug in the UK for use as add-on therapy for 
refractory partial epilepsy. It has multiple modes of action involving voltage-dependent sodium channels, GABA 
receptors and glutamate receptors. Topiramate has very favourable pharmacokinetics as it is primarily excreted 
unchanged. Its metabolism is, however, increased by enzyme inducers, and it can inhibit the metabolism of 
phenytoin in some patients. Its efficacy as adjunctive treatment in refractory partial epilepsy in adults appears good, 
over 40% of patients have a 50% or greater reduction in seizure frequency when topiramate is added to their 
regime with up to 7% becoming seizure free. The main adverse events are ataxia, impaired concentration, 
confusion, dizziness, fatigue, parasthesia, somnolence and ‘thinking abnormal’. Most of these occurred during rapid 
titration. During long-term treatment, weight loss also occurred and nephrolithiasis occurred in 1.5% of patients 
receiving topiramate. Topiramate is a useful and well-tolerated addition to our treatment of refractory epilepsy, but 
it should be titrated slowly in order to avoid adverse events. 
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INTRODUCTION 
There are two main reasons for new antiepileptic 
drug (AED) development: (1) to develop AEDs 
for use in patients with epilepsy resistant to 
available AEDs and (2) to develop AEDs with 
better side-effect and pharmacokinetic profiles 
than currently available AEDs. Approximately 
20% of patients with epilepsy are resistant to 
therapy with first line AED treatment and only 
the minority of these patients are amenable to 
epilepsy surgery’. The effect of new AEDs on the 
prognosis of this population group has been 
disappointing, and new, more effective AEDs are 
still required2. Topiramate is a recently licensed 
and marketed (October 1995) AED in the UK for 
use as add-on therapy for partial seizures with or 
without secondarily generalized seizures in pati- 
ents inadequately controlled on conventional first 
line antiepileptic treatment. Despite its recent 
marketing, there is still a dearth of information on 
topiramate in peer-reviewed journals and thus 
unfortunately much of the information on the 
drug has been gleaned from personal knowledge, 
abstracts and product monographs. 
MECHANISM OF ACTION 
Topiramate (2,3;4,5-bis-O-(l-methylidene)-beta- 
D-fractopyranose sulphamate) is a sulphamate- 
substituted monosaccharide which exhibits some 
inhibition of carbonic anhydrase, but whose 
action is likely to be independent of this effect. 
Acetazolamide-tolerant mice are not tolerant to 
topiramate, implying that these AEDs act by 
different mechanisms3. It is effective against 
maximal electroshock, but not chemically- 
induced seizures in rats, and thus in animal 
models has a similar spectrum of activity to 
phenytoin3. Topiramate appears to have multiple 
modes of action. It acts at voltage-dependent 
sodium channels blocking the spread of seizures4, 
it enhances GABAA evoked chloride currents at 
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a non-benzodiazepine receptor site’ and it an- 
tagonises AMPA subtype glutamate receptors6. 
The role of this latter mechanism is still unclear. 
PHARMACOKINETICS 
In healthy volunteers, topiramate is well ab- 
sorbed following oral ingestion with a time to 
maximum concentration of 2-4 hours’. The rate 
of absorption may be slowed by food, but the 
extent of absorption remains unchanged’. It has 
minimal binding to plasma proteins (15%). It has 
linear and predictable pharmacokinetics, and it is 
predominantly excreted unchanged in the urine 
with an elimination half-life of 19-23 hours’. 
Topiramate does however undergo some meta- 
bolism and the plasma concentrations and half- 
life of topiramate are reduced by phenytoin, and 
carbamazepine”‘. Topiramate should thus be 
taken at least twice daily. 
Topiramate has no effect on the plasma 
concentrations of carbarnazepine’O. There is some 
evidence that the area under the concentration vs. 
time curve for phenytoin is greater with co- 
administration of topiramate in a few patients”. 
This interaction is possibly due to topiramate 
inhibiting the uncommon CYP2C19 isoform of 
cytochrome P45013. This isoform has other 
substrates such as diazepam and omeprazole, and 
thus topiramate could inhibit the metabolism of 
these”. However, topiramate does not inhibit any 
other CYP450 isoforms and thus would be 
expected to have very few inhibition based drug 
interactionsX3. In patients with epilepsy, there 
appears to be no clinically significant interaction 
between valproic acid and topiramate14. How- 
ever, topiramate does induce a significant change 
in the valproate metabolic profile, a fall in 
glucuronide conjugates was accompanied by a 
small increase in oxidative metabolites of 
valproate15. The significance of this is unknown. 
There is an interaction with the contraceptive pill; 
contraceptive pills containing at least 50 pg of 
oestrogen should be used6. There is no correla- 
tion between plasma concentrations and either 
median percent reduction in seizure rates or 
percentage responders16. Statistically significant 
increases in mean plasma concentrations oc- 
curred in patients experiencing weight loss and 
anorexia, and there was a trend towards higher 
plasma concentrations for those experiencing 
adverse events16. Thus overall topiramate has 
favourable pharmacokinetics, which compare 
well with recently licensed AEDs, and AEDs 
presently still under development”. 
EFFICACY IN HUMANS 
Preliminary results from trials suggest that 
topiramate is useful in partial seizures and in 
patients with Lennox-Gastaut syndrome’8-22. In 
these trials doses of up to 1800 mg/day were well 
tolerated, and in the USA trials are underway 
with doses as high as 48OOmgldap. Five 
double-blind, placebo-controlled, randomized 
trials of topiramate (200-1000 mg) as add-on in 
refractory partial epilepsy (total of 534 patients) 
have been carried out in the US and Europe24. 
Topiramate produced a significant reduction in 
secondarily generalized, complex partial and 
simple partial seizure rates. Significantly more 
patients (19%) on topiramate than placebo had a 
75% reduction in seizures, and significantly more 
became seizure free (4%)*“. This last figure 
compares well with a meta-analysis of other new 
drugs in which less than 2% of patients became 
seizure free*. Responder rates (patients with a 
50% or greater reduction in seizures) in the 
European double blind studies were 35% for 
400 mg/day, 47% for 600 mg/daJ6 and 43% for 
800 mg/daf’. In this last trial 7% became seizure 
free*‘. In a novel trial design, topiramate low dose 
(100 mg/day) was compared with topiramate high 
dose (1000 mg/day) in a double-blind fashion in 
patients with refractory epilepsy who had had 
their concomitant AEDs withdrawn=. This trial 
lasted 112 days, but patients were withdrawn 
from the trial if they met any of a set of criteria 
that were used to determine if seizure control had 
deteriorated from baseline. Overall, time to 
withdrawal was longer for those taking 
1000 mg/day topiramate and significantly more of 
this group completed the trialz. 
TOLERABILITY AND SAFETY 
There has been over 2000-person years of 
experience with topiramate and it appears to be 
well tolerated6. Overall in the double blind 
studies ataxia, impaired concentration, confusion, 
dizziness, fatigue, parasthesia, somnolence and 
‘thinking abnormal’ occurred in 5% or more 
patients6. Over 80% of patients who experienced 
adverse events during titration did not continue 
to report these events by the fourth month6. Thus 
many of these adverse events may have been due 
to the rapid (3-6 week) titration that occurred 
during these trials. During long-term treatment 
weight loss also occurred, this happened in the 
first three months of treatment and peaked by 
12-15 months of treatment6. 
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Nephrolithiasis occurred in 1.5% of patients 
treated with topiramate; the annual incidence is 
similar to that of nephrolithiasis caused by 
acetazolamide*‘. In cases where analysis was 
performed the stones were primarily calcium 
phosphate stones. The mechanism of action of 
nephrolithiasis caused by topiramate is likely to 
be related to decreased citrate excretion3’. So far 
no other serious idiosyncratic reactions to topira- 
mate have been identified. 
Teratogenic effects of topiramate have been 
noted in animal models and are similar to those 
observed with acetazolamide. They mainly con- 
sist of skeletal malformations including: right- 
sided ectrodactyl and rib and vertebral malfor- 
mations in rabbit@. 
The total withdrawal rate due to adverse events 
in the double-blind studies was approximately 
14% with the majority of these withdrawals 
occurring during the titration phase”. This figure 
is higher than that seen in the double-blind trials 
of gabapentin, vigabatrin and lamotrigine31, and it 
may be related to the titration rate of topiramate 
being too rapid, although this requires further 
investigation. 
Carbonic anhydrase inhibitors can produce 
gastric hyperplasia, by decreasing gastric acid 
secretion and consequently causing increased 
gastrin levels. Topiramate, however, did not have 
significant gastrointestinal adverse events6 and 
furthermore an endoscopic study in eight patients 
on long-term topiramate treatment (3 years) 
demonstrated no effect of topiramate on gastric 
levels or gastric mucosal histology*. 
Topiramate has also been used in children and 
has been found to be safe, well-tolerated and easy 
to titrate33. In one paediatric trial, topiramate was 
introduced at a dose of 1 mg/kg/day for the first 
week increasing to 3mg/kg/day for the second 
week, 6 mg/kg/day for the third week and then 
finally 9 mg/kg/day for the fourth week33. 
CLINICAL USE 
Topiramate is available in 25 mg, 50 mg, 100 mg 
and 200 mg tablets. The minimal effective dose 
appears to be 200 mg and most patients will need 
200-6OOmg/day in divided doses. During the 
trials, withdrawals and adverse events may have 
been due to rapid titration of topiramate, and it 
should thus be titrated slowly. The recommended 
starting dose is lOOmg/day in divided doses 
increasing after one week to 2OOmg/day in 
divided doses. Thereafter the dose can be 
increased by 200 mg/day increments weekly up to 
a maximum dose of 8OOmg/day. Some patients 
require an even slower titration, and certainly 
those patients who are not taking an enzyme 
inducer could benefit from an initial starting dose 
of 25-50 mg/day increasing by 25-50 mg/day 
increments weekly up to 200 mg/day in divided 
doses. Thereafter increments of 100 mg/day 
weekly should be used up to a maximum dose of 
8OOmg/day. Patients with renal impairment 
require a slower titration (2 weekly increments) 
and will generally require lower doses”. Hepatic 
impairment has only a minimal effect on topiram- 
ate kinetics, as does age6. Patients on phenytoin 
should have their phenytoin plasma concentra- 
tions monitored. Withdrawal of topiramate 
should occur by lOOmg/day weekly, although 
faster withdrawal rates have been tolerated. 
CONCLUSION 
Topiramate is a new AED with a novel mechan- 
ism of action and favourable pharmacokinetics. 
Its tested efficacy as adjunctive treatment in 
refractory partial epilepsy in clinical trials com- 
pares with other new AEDs. There have also 
been reports of its effectiveness in Lennox- 
Gastaut and other epilepsy syndromes, although 
the results of trials in these patient groups are 
awaited. Topiramate predominantly has CNS 
side-effects that are common to most AEDs, and 
these adverse events usually occurred during 
rapid titration. During double-blind trial, with- 
drawal rates due to adverse events appeared to be 
slightly greater than that seen with other new 
AEDs, but again this may be related to rapid 
titration. Renal stones occurred in approximately 
1.5% of patients (i.e. with a similar frequency in 
acetazolamide). 
Topiramate appears to be an effective and 
well-tolerated addition to our range of AEDs. 
However, as with all new AEDs, a number of 
caveats need to be made. The first is that the 
development of tolerance and some long-term 
side-effects may not be evident because of the 
time limit imposed on AED trials. The second is 
that the total number of patients included in 
AED trials is relatively small, and thus rare but 
clinically important side-effects like, for example, 
aplastic anaemia may be missed (as occurred with 
the new AED felbamate). Thirdly, new AED 
trials exclude pregnant patients or those on 
inadequate contraception, and thus there are 
scarce data on the safety of new AEDs during 
pregnancy and on the developing foetus. Lastly, 
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drug trials are performed in selected population 
and the drug could have a different side-effect and 
tolerability profile in different population groups. 
These problems emphasise the importance of 
case reporting and notification in early and even 
late post-marketing phases. The eventual role of 
topiramate (as, indeed, most new AEDs) in the 
treatment of epilepsy remains to be determined, 
and only clinical experience over many years will 
answer this question. Topiramate does, however, 
appear to be a useful addition to the treatment of 
refractory epilepsy. 
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